Brief: Rigel Expands Relationship With Kissei To Include Rezlidhia (Olutasidenib) In Japan, The Republic Of Korea And Taiwan

Rigel Pharmaceuticals

03/09/2024 13:47

Sept 3 (Reuters) - Rigel Pharmaceuticals Inc  RIGL.O :
    * RIGEL EXPANDS RELATIONSHIP WITH KISSEI TO INCLUDE
REZLIDHIA®
(OLUTASIDENIB) IN JAPAN, THE REPUBLIC OF KOREA AND TAIWAN
    * RIGEL-TO GET UPFRONT CASH PAYMENT OF $10.0 MILLION WITH
POTENTIAL FOR UP TO $152.5 MILLION IN FUTURE DEVELOPMENT,
REGULATORY, COMMERCIAL MILESTONE PAYMENTS
    * RIGEL PHARMACEUTICALS INC - KISSEI RECEIVES EXCLUSIVE
RIGHTS TO
REZLIDHIA IN AML AND ALL FUTURE INDICATIONS IN JAPAN, KOREA AND
TAIWAN
    * RIGEL PHARMACEUTICALS- TO GET PRODUCT TRANSFER PRICE
PAYMENTS IN
MID-20 TO LOWER-30% RANGE BASED ON TIERED NET SALES FOR
EXCLUSIVE SUPPLY OF REZLIDHIA

Source text for Eikon:  ID:nPncgh1B3a 
Further company coverage:  RIGL.O 

 ((Reuters.Brief@thomsonreuters.com;))